Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis.
about
Antigenized antibodies expressing Vbeta8.2 TCR peptides immunize against rat experimental allergic encephalomyelitisT-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosisAutoimmune disease and the nervous system. Biochemical, molecular, and clinical update.Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein.Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis.Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptidesT-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable-region V beta 8.2-positive T cells are not essential for induction and course of disease.Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitisSelective immunointervention in autoimmune diseases: lessons from multiple sclerosis.TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion.CD8alpha+ dendritic cells prime TCR-peptide-reactive regulatory CD4+FOXP3- T cellsNovel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.Identification of new therapeutic targets for prevention of CNS inflammation.Idiotypes of DNA-binding antibodies: recent advances.Autoreactive T cells in multiple sclerosis.Antigen-specific tolerance as a therapy for experimental autoimmune encephalomyelitis.EAE: a model for immune intervention with synthetic peptides.Myelin specific, autoaggressive T cell clones in the normal immune repertoire: their nature and their regulation.Autoimmune thyroiditis and targeted anti-T cell immunotherapy in man.Oligoclonal T cell repertoire in cerebrospinal fluid of patients with inflammatory diseases of the nervous system.Heterogeneity of T-cell receptor alpha-chain complementarity-determining region 3 in myelin basic protein-specific T cells increases with severity of multiple sclerosis.CDR1 T-cell receptor beta-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions.Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium.T-lymphocytes and the pathogenesis of type 1 (insulin-dependent) diabetes mellitus.A synthetic peptide from the third hypervariable region of major histocompatibility complex class II beta chain as a vaccine for treatment of experimental autoimmune encephalomyelitisEncephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaquesAutoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.A public T cell clonotype within a heterogeneous autoreactive repertoire is dominant in driving EAE.Homeostatic control of immunity by TCR peptide-specific TregsTregs in T cell vaccination: exploring the regulation of regulation.1991 Mack Forster Award Lecture. HLA and disease: from epidemiology to immunotherapy.Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update.Feedback regulation of autoimmunity via TCR-centered regulation.A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosisAnalysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment
P2860
Q24791647-AC50AAB4-7298-4195-8119-8E5E2A9213BFQ28155795-6AA1D523-BAB1-4C9D-B437-49122DC17EE4Q33560305-D9EF2AEE-EEBF-4082-850A-C7FD2368F079Q33713319-8A1E33CE-64D5-4868-A800-F371EAA0C88EQ33831379-5A19CE6D-F293-4371-95E5-859E5D2B3491Q33842739-D720C02D-860A-4711-8EDD-085D6341566DQ33909622-6C8D43DC-29F9-4BB4-8839-D4E212D8943AQ34091080-1F49E7A5-2960-4DED-B885-61E118A00EBFQ34158763-20CB601D-8536-42CB-A9B8-A0C8B4B3DBFFQ34159098-CAD8F571-ED3D-4FB4-8B65-B754A50FD7BFQ34224070-A28D6171-62B0-4AA3-A11E-677DCFCB2579Q34234228-824724C9-A7FE-446C-B853-80C38C0B1CA7Q34307160-52439E18-96BC-4CA3-9192-B9856DC6FA91Q34378771-1F2426A1-4F5D-4E38-82D2-7CB759EE33BFQ34542206-2F177360-51FC-48AD-9E55-285EE6B30992Q34792611-DA015F04-D224-4F58-A639-0479847F0DEDQ34837632-C1B6FE35-AAFD-4281-8327-2CD3E2321B70Q35170672-C0CB900D-EB09-4B1D-833B-369DF1437A13Q35173092-F618CFC8-72BE-4662-9D75-3C8536A3F817Q35173096-28728A26-7B10-4F3F-8649-B51BDE902373Q35173105-C23D96E4-7F39-4374-8271-BA3B17A34953Q35173119-CB53EE7E-DA79-4866-B49B-DE3C8607B33BQ35315562-B4A8CFA0-8965-4418-A878-59785B961826Q35462517-74743273-DA1B-42AC-B5DF-C5671B274930Q35491552-BCDDF66E-7E7D-496C-A0E3-3E0EB1BBEE9CQ35546583-D395FF05-574F-4754-9DBC-190A927541EFQ35604657-856CCCA9-184C-44F6-B654-3F44EE0CB506Q35654189-BA0285B3-8911-41CA-9308-D8AB9AE7A1B9Q35677102-EDCC73D2-73B0-4F2F-A7D2-5C8536CA9E72Q35764710-B538B2EE-B869-4667-B288-A027ABB67494Q35861182-7692E4F0-FBBC-409E-867E-7CCFE8A5075DQ35868821-89A359EB-88E2-4971-ACD5-3AB201D985EEQ35936495-C5AF71F7-8004-43B7-A89F-3177D5EDC112Q35936500-584D5E86-C083-4023-A254-0D0511E367BAQ35981919-A3CD4858-A26E-4799-9B66-F321F92A029AQ36179710-B01ED224-E492-43A3-A84E-33B4F5325FA3Q36203561-104BE6CB-7555-4065-A895-4E6B384B07D5Q36229747-8BA38468-A01B-4A4F-90BC-D181A2253DC3Q36230631-2E887C71-9176-4753-9139-8A9C1774CBB1Q36230664-897D62BD-AE3D-44C0-B828-9F0C0475233E
P2860
Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Immunization with a synthetic ...... autoimmune encephalomyelitis.
@en
Immunization with a synthetic ...... autoimmune encephalomyelitis.
@nl
type
label
Immunization with a synthetic ...... autoimmune encephalomyelitis.
@en
Immunization with a synthetic ...... autoimmune encephalomyelitis.
@nl
prefLabel
Immunization with a synthetic ...... autoimmune encephalomyelitis.
@en
Immunization with a synthetic ...... autoimmune encephalomyelitis.
@nl
P2093
P356
P1433
P1476
Immunization with a synthetic ...... autoimmune encephalomyelitis.
@en
P2093
P2888
P304
P356
10.1038/341541A0
P407
P577
1989-10-01T00:00:00Z
P5875
P6179
1019136001